

**BIOGRAPHICAL SKETCH**  
**Complete for each professional associated with the project**

Name: <i>[Last, First, Middle Initial(s), Degree(s)]</i> <b>Malucchi Simona, MD</b>	Position/Title: <b>Neurologist</b>
--	---------------------------------------

**Education**

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Turin	Bachelor degree	1997	Research Thesis on neutralizing antibodies against Interferon beta
University of Turin	Neurologist	2003	Research Thesis on biological activity of interferon beta

## **Research and Professional Experience**

[List in chronological order, previous employment, experience and honors]

1998-2003: Resident at University of Turin, University Hospital San Luigi Gonzaga, Orbassano (Turin).

2003-2007: scholarship at CReSM (Centro di Riferimento Regionale Sclerosi Multipla), University Hospital San Luigi Gonzaga.

2007- to date: Neurologist at SCDO Neurologia-CReSM (Centro di Riferimento Regionale Sclerosi Multipla), University Hospital San Luigi Gonzaga.

2007-2014: sub-investigator in several Phase II and III clinical trials on Multiple Sclerosis

2010-2014: Principal Investigator of the research project sponsored by FISM "Longitudinal study of neuropsychological functioning in MS patients in comparison to general population".

2014 to date: Principal investigator in several Phase II and III clinical trials on Multiple Sclerosis.

## Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

- Malucchi S**, Capobianco M, Lo Re M, Malentacchi M, di Sapio A, Matta M, Sperli F, Bertolotto A. High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study. *Neurol Ther*. 2016 Dec 3.PMID: 27915429
- Borghini M, Carletto S, Ostacoli L, Scavelli F, Pia L, Pagani M, Bertolotto A, **Malucchi S**, Signori A, Cavallo M. Decline of Neuropsychological Abilities in a Large Sample of Patients with Multiple Sclerosis: A Two-Year Longitudinal Study. *Front Hum Neurosci*. 2016 Jun 8;10:282. doi: 10.3389/fnhum.2016.00282.
- Troni W, Melillo F, Bertolotto A, **Malucchi S**, Capobianco M, Sperli F, Di Sapio A. Normative Values for Intertrial Variability of Motor Responses to Nerve Root and Transcranial Stimulation: A Condition for Follow-Up Studies in Individual Subjects. *PLoS One* 2016 May 16;11(5):e0155268. doi: 10.1371/journal.pone.0155268.
- Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, **Malucchi S**, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Cytokine profiles show heterogeneity of interferon- $\beta$  response in multiple sclerosis patients. *Neurol Neuroimmunol Neuroinflamm*. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202.
- Capobianco M, di Sapio A, Malentacchi M, **Malucchi S**, Matta M, Sperli F, Bertolotto A. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. *Eur J Neurol*. 2015 Mar;22(3):585-7. doi: 10.1111/ene.12487.
- Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Iorio M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Trojano M, Zaffaroni M, **Malucchi S**; Italian Multiple Sclerosis Study group. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. *Neurol Sci*. 2014 Feb;35(2):307-16. doi: 10.1007/s10072-013-1616-1. Erratum in: *Neurol Sci*. 2014 Oct;35(10):1645-6. Troiano, Maria [corrected to Trojano, Maria].
- Hegen H, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, **Malucchi S**, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. *Mult Scler*. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597.
- Borghini M, Cavallo M, Carletto S, Ostacoli L, Zuffranieri M, Picci RL, Scavelli F, Johnston H, Furlan PM, Bertolotto A, **Malucchi S**. Presence and significant determinants of cognitive impairment in a large sample of patients with multiple sclerosis. *PLoS One*. 2013 Jul 29;8(7):e69820. doi: 10.1371/journal.pone.0069820.
- Gilli F, Navone ND, Perga S, Marnetto F, Caldano M, Capobianco M, Pulizzi A, **Malucchi S**, Bertolotto A. Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis. *Arch Neurol*. 2011 Jul;68(7):879-88. doi: 10.1001/archneurol.2011.32.
- Malucchi S**, Gilli F, Caldano M, Sala A, Capobianco M, di Sapio A, Granieri L, Bertolotto A. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. *J Neurol*. 2011 May;258(5):895-903. doi: 10.1007/s00415-010-5844-5.
- Capobianco M, Rizzo A, **Malucchi S**, Sperli F, Di Sapio A, Oggero A, Zaffaroni M, Ghezzi A, Bertolotto A. Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. *Neurol Sci*. 2008 Sep;29 Suppl 2:S227-9. doi: 10.1007/s10072-008-0945y.
- Malucchi S**, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A. Predictive markers for response to interferon therapy in patients with multiple sclerosis. *Neurology*. 2008 Mar 25;70(13 Pt 2):1119-27. doi: 10.1212/01.wnl.0000304040.29080.7b.
- Gilli F, Marnetto F, Caldano M, Sala A, **Malucchi S**, Capobianco M, Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. *Mult Scler*. 2006 Feb;12(1):47-57.
- Malucchi S**, Capobianco M, Gilli F, Marnetto F, Caldano M, Sala A, Bertolotto A. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments. *Neurol Sci*. 2005 Dec;26 Suppl 4:S213-4.
- Malucchi S**, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. *Neurology*. 2004 Jun 8;62(11):2031-7.

**Firma**